Thursday, November 27, 2014 Last update: Yesterday, 8:03 PM - Covering Large & Obscure Tech Companies Since 1996

Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference

Companies mentioned in this article: Aerie Pharmaceuticals, Inc.

BEDMINSTER, N.J., RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. -- (BUSINESS WIRE) -- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 11:30a.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerie’s website at A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company has commenced two Phase 3 registration trials in the United States, named "Rocket 1" and "Rocket 2," where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, and has received a "no objection letter" from Health Canada to initiate a third Phase 3 safety trial, named "Rocket 3," in Canada. The Company also recently completed a Phase 2b clinical trial where RoclatanTM met the primary efficacy endpoint, demonstrating statistical superiority of Roclatan™ to each of its components.

Copyright © Business Wire 2014

Aerie Pharmaceuticals
Richard Rubino, 908-470-4320
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Angeli Kolhatkar, 212-213-0006